NO944910L - Method of Inhibiting Obsessive-Compulsive Conditions and Eating Disorders - Google Patents

Method of Inhibiting Obsessive-Compulsive Conditions and Eating Disorders

Info

Publication number
NO944910L
NO944910L NO944910A NO944910A NO944910L NO 944910 L NO944910 L NO 944910L NO 944910 A NO944910 A NO 944910A NO 944910 A NO944910 A NO 944910A NO 944910 L NO944910 L NO 944910L
Authority
NO
Norway
Prior art keywords
eating disorders
obsessive
compulsive
inhibiting
conditions
Prior art date
Application number
NO944910A
Other languages
Norwegian (no)
Other versions
NO944910D0 (en
Inventor
Edward Paul Gray
James Joseph Sales
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944910D0 publication Critical patent/NO944910D0/en
Publication of NO944910L publication Critical patent/NO944910L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet en fremgangsmåte for Inhlberlng av obsessive-kompulslve tilstander eller inntaksforstyrr- elser Innbefattende administrering til en menneske som har behov for dette av en effektiv mengde av en ¿ forbindelse som har formelen ,OCH2CH2¿R2 (I) hvor R1 og R3 uavhengig av hverandre er hydrogen, -CH3, O O \\ II -C-(Ci-C6 alkyl), eller -C-Ar, hvor Ar er eventuelt substituert fenyl; R2 er valgt fra gruppen bestående av pyrrolldln, heksametylenamino og plperldlno; eller et farmasøytisk akseptabelt salt eller solvat derav.There is disclosed a method for the inclusion of obsessive-compulsive states or intake disorders, including administering to a human in need thereof an effective amount of a compound having the formula, OCH2CH2¿R2 (I) wherein R 1 and R 3 each other is hydrogen, -CH3, O0 \ II -C- (C1-C6 alkyl), or -C-Ar, where Ar is optionally substituted phenyl; R 2 is selected from the group consisting of pyrrolidine, hexamethyleneamino and piperidino; or a pharmaceutically acceptable salt or solvate thereof.

NO944910A 1993-12-21 1994-12-19 Method of Inhibiting Obsessive-Compulsive Conditions and Eating Disorders NO944910L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16848393A 1993-12-21 1993-12-21

Publications (2)

Publication Number Publication Date
NO944910D0 NO944910D0 (en) 1994-12-19
NO944910L true NO944910L (en) 1995-06-22

Family

ID=22611670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944910A NO944910L (en) 1993-12-21 1994-12-19 Method of Inhibiting Obsessive-Compulsive Conditions and Eating Disorders

Country Status (12)

Country Link
EP (1) EP0659428A1 (en)
JP (1) JPH07196494A (en)
KR (1) KR950016739A (en)
CN (1) CN1109331A (en)
AU (1) AU8155694A (en)
CA (1) CA2138458A1 (en)
CZ (1) CZ322494A3 (en)
HU (1) HUT71466A (en)
IL (1) IL112046A0 (en)
NO (1) NO944910L (en)
RU (1) RU94044323A (en)
ZA (1) ZA9410076B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012489A1 (en) * 1994-10-20 1996-05-02 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
EP0659428A1 (en) 1995-06-28
CA2138458A1 (en) 1995-06-22
ZA9410076B (en) 1996-06-19
IL112046A0 (en) 1995-03-15
CZ322494A3 (en) 1995-08-16
CN1109331A (en) 1995-10-04
AU8155694A (en) 1995-06-29
NO944910D0 (en) 1994-12-19
HU9403656D0 (en) 1995-02-28
RU94044323A (en) 1996-11-10
HUT71466A (en) 1995-11-28
KR950016739A (en) 1995-07-20
JPH07196494A (en) 1995-08-01

Similar Documents

Publication Publication Date Title
NO944911L (en) Non-peptide takykininreseptorantagonister
NO944928L (en) Methods for inhibiting Alzheimer's disease
NO944914L (en) Method of inhibiting autoimmune diseases
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
NO944919L (en) Method of inhibiting atrophy of the skin or vagina
ATE234094T1 (en) 2-PHENYL-3-AROYLBENZOTHIOPHENE FOR THE TREATMENT OF MENSTRUAL SYMPTOMS
NO944927L (en) Method for inhibiting pulmonary hypertensive disease
DK0652005T3 (en) Methods for inhibiting endometriosis
DK0651999T3 (en) Methods for inhibiting uterine fibrosis
NO944930L (en) Inhibition of dysfunctional uterine bleeding
MX9701325A (en) Methods of inhibiting ulcerative mucositis.
KR950016731A (en) How to suppress seborrhea and acne
UA32427C2 (en) The use of benzothiophene or pharmaceutical acceptable salts or solvate thereof for inhibition of angiogenesis and/or angiogenic diseases
NO944926L (en) Methods for Inhibiting Myeloperoxidase Activity
NO944924L (en) Procedures for inhibiting Turner's syndrome
NO944933L (en) Procedure for inhibiting disease states of the breast
NO944917D0 (en) Use of 2-phenyl-3-aroylthiophenes for inhibition of ovarian dysgenesis, delayed puberty or sexual infantilism
NO975580L (en) Method of inhibiting melanoma
NO944931L (en) Use of 2-phenyl-3-aroylbenzothiophenes for inhibiting early sexual maturity
NO944923L (en) Inhibition of weight gain or induction of weight loss
NO944910L (en) Method of Inhibiting Obsessive-Compulsive Conditions and Eating Disorders
NO981578L (en) Method of inhibiting plasminogen activator inhibitor I
NO973609L (en) Method of inhibiting the effects of IL-6
NO944577L (en) Inhibition of the effect of amyloidogenic proteins
NO973103L (en) Method for inhibiting growth hormone effects